Paper Review Records
All Paper Review Records
13 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Chromosomal instability does not correlate with metastatic potential in human cancer cell lines
Greta Mühlmeier; Carolin Feldmann; Timothy Wohlfromm; Bianca N. Kraft; Alwin KrämerShow moreShow less
1. Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; 2. Center for Pediatrics and Adolescent Medicine, Hannover Medical School (MHH), Hannover, Germany; 3. Department of Medical Oncology, National Center for Tumor Diseases (NCT), University of Heidelberg, Heidelberg, Germany; 4. Department of Internal Medicine V, University of Heidelberg, Heidelberg, GermanyShow moreShow less
Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis
Jiamin Lu; Yuqian Feng; Kaibo Guo; Leitao Sun; Shanming Ruan; Kai ZhangShow moreShow less
1. The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China; 2. The First Affiliated Hospital of Zhejiang, Chinese Medical University, (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China; 3. Hangzhou TCM Hospital of Zhejiang Chinese Medical University, Hangzhou, China; 4. Department of Oncology, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China; 5. Anji Traditional Chinese Medical Hospital, Huzhou, ChinaShow moreShow less
The effect of resistin on the redox state of breast cancer cells
Elitsa Pavlova; Radoslav Stojchevski; Dimiter AvtanskiShow moreShow less
1. Faculty of Physics, Sofia University “St. Kliment Ohridski”, Sofia, Bulgaria; 2. Friedman Diabetes Institute, Lenox Hill Hospital, Northwell Health, New York, USA; 3. Donald and Barbara Zucker School of Medicine at Hofstra, Northwell, Hempstead, USA; 4. Feinstein Institutes for Medical Research, Manhasset, NY, USAShow moreShow less
Immunogenic profiling of metastatic uveal melanoma discerns a potential signature related to prognosis
Jian Wang; Miaomiao Liu; Jiaxing Sun; Zifeng ZhangShow moreShow less
1. Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi’an, China; 2. Department of Respiratory, Tangdu Hospital, Fourth Military Medical University, Xi’an, China; 3. Department of Ophthalmology, Eye Institute of Chinese PLA, Xijing Hospital, Fourth Military Medical University, Xi’an, ChinaShow moreShow less
Hypofractionated versus standard chemoradiotherapy in the definitive treatment of uterine cervix cancer: interim results of a randomized controlled clinical trial
Afsane Maddah Safaei; Ebrahim Esmati; Marzieh Gomar; Setareh Akhavan; Shahrzad Sheikh Hasani; Mona Malekzadeh Moghani; Narges Zamani; Maryam Moshtaghi; Mahrooz Malek; Fatemeh Jafari; Azadeh Sharifian; Kasra KolahdouzanShow moreShow less
1. Radiation Oncology Research Center (RORC), Cancer Research Institute, Tehran University of Medical Sciences, Tehran, Iran; 2. Department of Obstetrics and Gynecology, Vali-Asr Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran; 3. Department of Oncologic Gynecology, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran; 4. Department of Radiation Oncology, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 5. Radiation Oncology Department, Booali Hospital, Tehran, Iran; 6. Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Radiology Department, Imam Khomeini Hospital Complex (IKHC), Tehran University of Medical Sciences, Tehran, IranShow moreShow less
Predictive biomarkers for immunotherapy response in extensive-stage SCLC
Lin Zhu; Jing QinShow moreShow less
1. Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China; 2. Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology (Lung and Esophagus), Zhejiang Cancer Hospital, Hangzhou, People’s Republic of ChinaShow moreShow less
FAQ
How long does JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY take to review a manuscript?
As of 2026-11-19, CrushSCI has 13 complete review records for JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. The fastest paper went from submission to acceptance in 19 days (Long-term survival of stage IV melanoma patients: evaluation on 640 melanoma patients entering stage IV between 2014 and 2017, received 2023-10-26, accepted 2023-11-14); the slowest took 203 days. The average is 71.5 days and the median is 55 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
